119 related articles for article (PubMed ID: 37243926)
21. Improved outcomes with dose-dense paclitaxel-based neoadjuvant chemotherapy in advanced epithelial ovarian carcinoma.
Becker DA; Thomas ED; Gilbert AL; Boone JD; Straughn JM; Huh WK; Bevis KS; Leath CA; Alvarez RD
Gynecol Oncol; 2016 Jul; 142(1):25-29. PubMed ID: 27130405
[TBL] [Abstract][Full Text] [Related]
22. Bevacizumab combined with platinum-taxane chemotherapy as first-line treatment for advanced ovarian cancer: a prospective observational study of safety and efficacy in Japanese patients (JGOG3022 trial).
Komiyama S; Kato K; Inokuchi Y; Takano H; Matsumoto T; Hongo A; Asai-Sato M; Arakawa A; Kamiura S; Tabata T; Takeshima N; Sugiyama T
Int J Clin Oncol; 2019 Jan; 24(1):103-114. PubMed ID: 30030657
[TBL] [Abstract][Full Text] [Related]
23. Genetic predisposition to bevacizumab-induced hypertension.
Frey MK; Dao F; Olvera N; Konner JA; Dickler MN; Levine DA
Gynecol Oncol; 2017 Dec; 147(3):621-625. PubMed ID: 28969913
[TBL] [Abstract][Full Text] [Related]
24. Phase II trial of docetaxel and carboplatin in recurrent platinum-sensitive ovarian, peritoneal and tubal cancer.
Strauss HG; Henze A; Teichmann A; Karbe I; Baumgart A; Thomssen C; Koelbl H
Gynecol Oncol; 2007 Mar; 104(3):612-6. PubMed ID: 17069876
[TBL] [Abstract][Full Text] [Related]
25. Carboplatin re-treatment in platinum-resistant epithelial ovarian cancer patients.
Hansen MKG; Smerdel MP; Waldstrøm M; Andersen RF; Adimi P; Jakobsen A; Steffensen KD
Cancer Chemother Pharmacol; 2020 Dec; 86(6):751-759. PubMed ID: 33067703
[TBL] [Abstract][Full Text] [Related]
26. Pharmacogenomics of taxane/platinum therapy in ovarian cancer.
Marsh S
Int J Gynecol Cancer; 2009 Dec; 19 Suppl 2():S30-4. PubMed ID: 19955911
[TBL] [Abstract][Full Text] [Related]
27. Phase II study of carboplatin, docetaxel and bevacizumab for chemotherapy-naïve patients with advanced non-squamous non-small cell lung cancer.
Takiguchi Y; Iwasawa S; Minato K; Miura Y; Gemma A; Noro R; Yoshimori K; Shingyoji M; Hino M; Ando M; Okamoto H
Int J Clin Oncol; 2015 Aug; 20(4):659-67. PubMed ID: 25301566
[TBL] [Abstract][Full Text] [Related]
28. Genetic variation in platinating agent and taxane pathway genes as predictors of outcome and toxicity in advanced non-small-cell lung cancer.
Lamba JK; Fridley BL; Ghosh TM; Yu Q; Mehta G; Gupta P
Pharmacogenomics; 2014; 15(12):1565-74. PubMed ID: 25340731
[TBL] [Abstract][Full Text] [Related]
29. Adjuvant chemotherapy with carboplatin and taxane compared with single drug carboplatin in early stage epithelial ovarian carcinoma.
Skírnisdóttir I; Lindborg K; Sorbe B
Oncol Rep; 2007 Nov; 18(5):1249-56. PubMed ID: 17914581
[TBL] [Abstract][Full Text] [Related]
30. A multicenter, non-randomized, phase II study of docetaxel and carboplatin administered every 3 weeks as second line chemotherapy in patients with first relapse of platinum sensitive epithelial ovarian, peritoneal or fallopian tube cancer.
Wang Y; Herrstedt J; Havsteen H; DePoint Christensen R; Mirza MR; Lund B; Maenpaa J; Kristensen G
BMC Cancer; 2014 Dec; 14():937. PubMed ID: 25494701
[TBL] [Abstract][Full Text] [Related]
31. A phase II study of gemcitabine, carboplatin and bevacizumab for the treatment of platinum-sensitive recurrent ovarian cancer.
Eisenhauer EL; Zanagnolo V; Cohn DE; Salani R; O'Malley DM; Sutton G; Callahan MJ; Cobb B; Fowler JM; Copeland LJ
Gynecol Oncol; 2014 Aug; 134(2):262-6. PubMed ID: 24910452
[TBL] [Abstract][Full Text] [Related]
32. Bevacizumab plus microtubule targeting agents in heavily pre-treated ovarian cancer patients: a retrospective study.
Asmane I; Kurtz JE; Bajard A; Guastalla JP; Meeus P; Tredan O; Labidi Galy I; Moullet I; Ardisson P; Vincent L; Coeffic D; Dufresne A; Bergerat JP; Ray-Coquard I
Bull Cancer; 2011 Oct; 98(9):80-9. PubMed ID: 21926034
[TBL] [Abstract][Full Text] [Related]
33. GSTP1 and ABCB1 Polymorphisms Predicting Toxicities and Clinical Management on Carboplatin and Paclitaxel-Based Chemotherapy in Ovarian Cancer.
Ferracini AC; Lopes-Aguiar L; Lourenço GJ; Yoshida A; Lima CSP; Sarian LO; Derchain S; Kroetz DL; Mazzola PG
Clin Transl Sci; 2021 Mar; 14(2):720-728. PubMed ID: 33326171
[TBL] [Abstract][Full Text] [Related]
34. Phase 1b study of anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) in patients with platinum-sensitive recurrent ovarian cancer.
Moore KN; Birrer MJ; Marsters J; Wang Y; Choi Y; Royer-Joo S; Lemahieu V; Armstrong K; Cordova J; Samineni D; Schuth E; Vaze A; Maslyar D; Humke EW; Hamilton EP; Liu JF
Gynecol Oncol; 2020 Sep; 158(3):631-639. PubMed ID: 32534811
[TBL] [Abstract][Full Text] [Related]
35. Carboplatin-paclitaxel compared to Carboplatin-Paclitaxel-Bevacizumab in advanced or recurrent endometrial cancer: MITO END-2 - A randomized phase II trial.
Lorusso D; Ferrandina G; Colombo N; Pignata S; Pietragalla A; Sonetto C; Pisano C; Lapresa MT; Savarese A; Tagliaferri P; Lombardi D; Cinieri S; Breda E; Sabatucci I; Sabbatini R; Conte C; Cecere SC; Maltese G; Scambia G
Gynecol Oncol; 2019 Dec; 155(3):406-412. PubMed ID: 31677820
[TBL] [Abstract][Full Text] [Related]
36. Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial.
Mirza MR; Åvall Lundqvist E; Birrer MJ; dePont Christensen R; Nyvang GB; Malander S; Anttila M; Werner TL; Lund B; Lindahl G; Hietanen S; Peen U; Dimoula M; Roed H; Ør Knudsen A; Staff S; Krog Vistisen A; Bjørge L; Mäenpää JU;
Lancet Oncol; 2019 Oct; 20(10):1409-1419. PubMed ID: 31474354
[TBL] [Abstract][Full Text] [Related]
37. Docetaxel and carboplatin as first-line chemotherapy in patients with advanced gynecological tumors. A phase I/II trial of the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO-OVAR) Ovarian Cancer Study Group.
Pfisterer J; du Bois A; Wagner U; Quaas J; Blohmer JU; Wallwiener D; Hilpert F;
Gynecol Oncol; 2004 Mar; 92(3):949-56. PubMed ID: 14984965
[TBL] [Abstract][Full Text] [Related]
38. Arthralgia in patients with ovarian cancer treated with bevacizumab and chemotherapy.
Ventriglia J; Paciolla I; Pisano C; Tambaro R; Cecere SC; Di Napoli M; Attademo L; Arenare L; Spina A; Russo D; Califano D; Losito NS; Setola SV; Franzese E; De Vita F; Orditura M; Pignata S
Int J Gynecol Cancer; 2021 Jan; 31(1):110-113. PubMed ID: 32796087
[TBL] [Abstract][Full Text] [Related]
39. Genes and variants in hematopoiesis-related pathways are associated with gemcitabine/carboplatin-induced thrombocytopenia.
Björn N; Sigurgeirsson B; Svedberg A; Pradhananga S; Brandén E; Koyi H; Lewensohn R; de Petris L; Apellániz-Ruiz M; Rodríguez-Antona C; Lundeberg J; Gréen H
Pharmacogenomics J; 2020 Apr; 20(2):179-191. PubMed ID: 31616045
[TBL] [Abstract][Full Text] [Related]
40. Endothelial nitric oxide synthase c.-813C>T predicts for proteinuria in metastatic breast cancer patients treated with bevacizumab-based chemotherapy.
Crucitta S; Restante G; Del Re M; Bertolini I; Bona E; Rofi E; Fontanelli L; Gianfilippo G; Fogli S; Stasi I; Ghilli M; Fontana A; Danesi R
Cancer Chemother Pharmacol; 2019 Dec; 84(6):1219-1227. PubMed ID: 31529205
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]